

 Formulary Hazardous Drug List
**Group 1. Antineoplastic Drugs (12)**

*Including those with the manufacturer's safe-handling guidance (MSHG)*

<b>anastrozole</b>	10:00		FDA Pregnancy Category X
<b>bacillus calmette guerin</b>	80:12	MSHG	BCG, although classified as a vaccine, is used in the treatment of certain cancers. BCG should be prepared with aseptic techniques. To avoid cross-contamination, parenteral drugs should not be prepared in areas where BCG has been prepared. A separate area for the preparation of BCG suspension is recommended. All equipment, supplies, and receptacles in contact with BCG should be handled and disposed of as biohazardous. If preparation cannot be performed in a containment device, then respiratory protection, gloves, and a gown should be worn to

			avoid inhalation or contact with BCG organisms. FDA Pregnancy Category C
<b>bleomycin</b>	10:00	MSHG	IARC Group 2B, Possibly Carcinogenic to Humans; FDA Pregnancy Category D
<b>fluorouracil</b>	10:00	MSHG	FDA Pregnancy Category D
<b>gemcitabine</b>	10:00	MSHG	FDA Pregnancy Category D
<b>hydroxyurea</b>	10:00	MSHG	Special warning on handling bottles and capsules; FDA Pregnancy Category D
<b>letrozole</b>	10:00		FDA Pregnancy Category X
<b>leuprolide</b>	10:00	MSHG	FDA Pregnancy Category X
<b>megestrol</b>	10:00		Nursing should be discontinued if megestrol is required; women at risk of pregnancy should avoid exposure; FDA Pregnancy Category X
<b>mercaptopurine</b>	10:00	MSHG	FDA Pregnancy Category D
<b>methotrexate</b>	10:00	MSHG	FDA Pregnancy Category X
<b>mitomycin</b>	10:00	MSHG	IARC Group 2B, Possibly Carcinogenic to Humans; FDA Pregnancy Category D

## Group 2. Non-antineoplastic Drugs (20)

*That meet one or more of the NIOSH criteria for a hazardous drug, including those with the manufacturer's safe-handling guidance (MSHG)*

Northeastern Vermont Regional Hospital

<b>azathioprine</b>	92:44	MSHG	<p>IARC Group 1, Carcinogenic to Humans; NTP, Known To Be Human Carcinogens; FDA Pregnancy Category D</p> <p>Meets one or more criteria for a hazardous drug and also poses a potential reproductive hazard</p>
<b>carbamazepine</b>	28:12:92		<p>Black Box warning for aplastic anemia; congenital malformations in offspring of mothers who took drug; rapid transplacental passage; FDA Pregnancy Category D</p> <p>Meets one or more criteria for a hazardous drug and also poses a potential reproductive hazard</p>
<b>cyclosporin</b>	92:44		<p>IARC Group 1, Carcinogenic to Humans; NTP, Known To Be Human Carcinogens; FDA Pregnancy Category C</p>
<b>divalproex</b>	28:12:92		<p>Black Box warning for teratogenicity; FDA Pregnancy Category D; tumors seen in laboratory studies at doses below MRHD</p> <p>Meets one or more criteria for a</p>

		hazardous drug and also poses a potential reproductive hazard
<b>estradiol</b>	68:16:04	<p>Black Box warning for malignant neoplasms; increased risk of endometrial cancer, breast cancer, and ovarian cancer; in laboratory studies, increased frequency of carcinomas of the breast, uterus, cervix, vagina, testis, and liver; present in breast milk; FDA Pregnancy Category X</p> <p>Meets one or more criteria for a hazardous drug and also poses a potential reproductive hazard</p>
<b>estrogen-progestin combinations</b>	68:12	<p>IARC Group 1, Carcinogenic to Humans; NTP, Known To Be Human Carcinogens; FDA Pregnancy Category X</p> <p>Meets one or more criteria for a hazardous drug and also poses a potential reproductive hazard</p>
<b>estrogens, conjugated</b>	68:16:04	<p>Black Box warning for endometrial cancer and cardiovascular risks; long-term use in women and laboratory studies increases frequency of several cancers; NTP, Known To Be Human Carcinogens; FDA Pregnancy Category X</p>

		Meets one or more criteria for a hazardous drug and also poses a potential reproductive hazard
<b>estrogens, esterified</b>	68:16:04	Black Box warning for endometrial cancer and cardiovascular risks; NTP, Known To Be Human Carcinogens; FDA Pregnancy Category X
		Meets one or more criteria for a hazardous drug and also poses a potential reproductive hazard
<b>fosphenytoin</b>	28:12.12	Metabolized to phenytoin; FDA Pregnancy Category D
		Meets one or more criteria for a hazardous drug and also poses a potential reproductive hazard
<b>medroxyprogesterone acetate</b>	68:32	IARC Group 2B, Possibly Carcinogenic to Humans; FDA Pregnancy Category X
		Meets one or more criteria for a hazardous drug and also poses a potential reproductive hazard
<b>methimazole</b>	68:36:08	Appears in human breast milk; FDA Pregnancy Category D
		Meets one or more criteria for a

<b>mycophenolate mofetil</b>	92:44	<p>hazardous drug and also poses a potential reproductive hazard</p> <p>Black Box warning for embryo fetal toxicity, malignancies, and serious infections; increased risk of first-trimester pregnancy loss and increased risk of congenital malformations; FDA Pregnancy Category D; Special warning: Tablets should not be crushed and capsules should not be opened or crushed. Avoid inhalation or direct contact with skin or mucous membranes of the powder contained in capsules and oral suspension(before or after constitution). If such contact occurs, wash thoroughly with soap and water; rinse eyes with plain water.</p> <p>Meets one or more criteria for a hazardous drug and also poses a potential reproductive hazard</p>
<b>oxcarbazepine</b>	28:12:92	<p>Tumors observed in laboratory studies at 1/10 MRHD; FDA Pregnancy Category C</p>
<b>phenytoin</b>	28:12:12	<p>IARC Group 2B, Possibly Carcinogenic to Humans; NTP, Reasonably Anticipated To Be Human Carcinogens; FDA Pregnancy Category D</p>

		Meets one or more criteria for a hazardous drug and also poses a potential reproductive hazard
<b>propylthiouracil</b>	68:36:08	IARC Group 2B, Possibly Carcinogenic to Humans; NTP, Reasonably Anticipated To Be Human Carcinogens; FDA Pregnancy Category D  Meets one or more criteria for a hazardous drug and also poses a potential reproductive hazard
<b>raloxifene</b>	68:16:12	Abortion and developmental abnormalities seen at low doses in laboratory studies; evidence of tumors at low doses in laboratory studies; FDA Pregnancy Category X  Meets one or more criteria for a hazardous drug and also poses a potential reproductive hazard
<b>risperidone</b>	28:16:08:04	As of January 10, 2019 this drug is no longer considered a hazardous drug by NIOSH.  2016 text: Evidence of tumors at low doses in laboratory studies; may be prolactin-mediated; FDA Pregnancy Category C

<b>spironolactone</b>	24:32.20		FDA Pregnancy Category C; Black Box warning for tumorigenicity in laboratory studies
<b>tacrolimus</b>	92:44		Increased risk of lymphomas and other malignancies; reproductive effects seen in laboratory studies below the MRHD; excreted in breast milk; FDA Pregnancy Category C
<b>valganciclovir</b>	8:18:32	MSHG	FDA Pregnancy Category C

### Group 3. Non-antineoplastic Drugs (22)

*That primarily have adverse reproductive effects*

<b>clonazepam</b>	28:12:08		Increased risk of congenital abnormalities when taken in first trimester; FDA Pregnancy Category D
<b>colchicine</b>	92:16		FDA Pregnancy Category C; published animal reproduction and development studies indicate it causes embryofetal toxicity, teratogenicity, and altered postnatal development at exposures within or above the clinical therapeutic range
<b>dinoprostone</b>	76:00		Hazardous only for women in late pregnancy; FDA Pregnancy Category C
<b>dronedarone</b>	24:04:04		Teratogenic in laboratory studies at ½ MRHD; FDA Pregnancy Category X



<b>dutasteride</b>	92:08	Women warned not to handle; FDA Pregnancy Category X Northeastern Vermont Regional Hospital
<b>finasteride</b>	92:08	Women should not handle crushed or broken finasteride tablets when they are pregnant or may potentially be pregnant, due to potential risk to a male fetus; FDA Pregnancy Category X
<b>fluconazole</b>	8:14.08	FDA Pregnancy Category C; case reports describe congenital anomalies in infants exposed in utero to maternal fluconazole (400–800 mg/day) during most or all of the first trimester, similar to those seen in animal studies
<b>methyltestosterone</b>	68:08	FDA Pregnancy Category X
<b>misoprostal</b>	56:28.28	FDA Pregnancy Category X
<b>oxytocin</b>	76:00	Hazardous only for women in 3rd trimester; FDA Pregnancy Category C
<b>pamidronate</b>	92:24	Embryo-fetal toxicities at doses below the recommended human dose; FDA Pregnancy Category D
<b>paroxetine</b>	28:16:04:20	Increased risk of congenital abnormalities when taken in first trimester; complications in pregnancy when taken in third trimester; FDA Pregnancy Category D
<b>temazepam</b>	28:24:08	

Increased risk of congenital malformations associated with treatment during the first trimester of pregnancy; FDA Pregnancy Category X

<b>testosterone</b>	68:08	Children should avoid contact with unwashed or unclothed application sites on skin; FDA Pregnancy Category X
<b>topiramate</b>	28:12:92	FDA Pregnancy Category D
<b>tretinoin</b>	84:16	Black Box warning for severe birth defects; Special FDA distribution system; FDA Pregnancy Category X
<b>valproate</b>	28:12:92	Black Box warning for teratogenicity; congenital malformations, including neural tube defects; teratogenic in multiple species; FDA Pregnancy Category D
<b>valproic acid</b>	28:12:92	Black Box warning for teratogenicity; congenital malformations, including neural tube defects; teratogenic in multiple species; FDA Pregnancy Category D
<b>warfarin</b>	20:12.04.08	FDA Pregnancy Category D
<b>ziprasidone</b>	28:16:08:04	Developmental toxicity, including possible teratogenic effects at doses similar to human therapeutic doses; an increase in the number of pups

		born dead and a decrease in postnatal survival at less than MRHD; FDA Pregnancy Category C
<b>zoledronic acid</b>	92:24	Number of stillbirths increased and survival of neonates decreased in laboratory studies at low doses; FDA Pregnancy Category D
<b>zonisamide</b>	28:12:92	Teratogenic in multiple miscellaneous animal species; FDA Pregnancy Category D